Profile data is unavailable for this security.
About the company
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
- Revenue in USD (TTM)118.55k
- Net income in USD-8.17m
- Incorporated2019
- Employees10.00
- LocationAltamira Therapeutics LtdClarendon House, 2 Church StreetHAMILTON 6300BermudaBMU
- Phone+41 612011350
- Websitehttps://aurismedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Resonate Blends Inc | 101.41k | -4.72m | 3.13m | 6.00 | -- | -- | -- | 30.82 | -0.0537 | -0.0537 | 0.0012 | -0.0007 | 0.0328 | -- | -- | -- | -152.56 | -680.29 | -- | -- | -34.87 | -78.88 | -4,657.83 | -12,895.26 | -- | -0.7413 | 1.02 | -- | -66.73 | -56.57 | -316.63 | -- | -- | -- |
Livewire Ergogenics Inc | 67.98k | -1.09m | 3.14m | 1.00 | -- | -- | -- | 46.24 | -0.0061 | -0.0061 | 0.0003 | -0.0022 | 0.1979 | 1.74 | 2.86 | 67,980.00 | -317.45 | -- | -- | -- | -113.70 | -- | -1,604.38 | -- | 0.1248 | -2.13 | -- | -- | 68.58 | -- | -3.64 | -- | -- | -- |
Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 3.16m | 40.00 | -- | -- | -- | 1.14 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 4.79 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
Revelation Biosciences Inc | 0.00 | -8.96m | 3.17m | 9.00 | -- | 0.3344 | -- | -- | -32.09 | -32.09 | 0.00 | 5.80 | 0.00 | -- | -- | 0.00 | -54.61 | -- | -91.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
Cyclacel Pharmaceuticals Inc | 449.00k | -19.85m | 3.18m | 12.00 | -- | -- | -- | 7.07 | -21.99 | -21.99 | 0.4636 | -1.67 | 0.0318 | -- | 0.1204 | -- | -139.57 | -57.58 | -314.22 | -69.81 | -- | -- | -4,386.86 | -18,789.29 | -- | -128.51 | -- | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
Aditxt Inc | 506.45k | -41.45m | 3.18m | 47.00 | -- | 0.3203 | -- | 6.28 | -109.80 | -109.80 | 0.7488 | 5.96 | 0.0284 | 0.9296 | 1.34 | 10,775.53 | -231.82 | -192.78 | -658.00 | -321.59 | -27.22 | -- | -8,149.75 | -7,208.65 | 0.0562 | -3.42 | 0.3915 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
Aptevo Therapeutics Inc | 0.00 | -27.31m | 3.28m | 40.00 | -- | 0.0888 | -- | -- | -98.49 | -97.90 | 0.00 | 9.06 | 0.00 | -- | -- | 0.00 | -103.85 | -47.16 | -134.86 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
Altamira Therapeutics Ltd | 118.55k | -8.17m | 3.32m | 10.00 | -- | 0.3013 | -- | 27.97 | -31.71 | -26.76 | 0.2413 | 4.91 | 0.0151 | 34.05 | 32.30 | 11,854.56 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -6,892.99 | -- | 1.38 | -4.36 | 0.0152 | -- | -- | -- | 61.02 | -- | -- | -- |
NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 3.32m | 24.00 | -- | -- | -- | 0.233 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
TRACON Pharmaceuticals Inc | 12.15m | 1.75m | 3.35m | 17.00 | 1.92 | -- | 1.90 | 0.2757 | 0.6509 | 0.6509 | 6.27 | -0.6618 | 1.37 | -- | -- | 714,411.80 | 19.78 | -79.42 | -- | -177.85 | -- | -- | 14.39 | -813.81 | -- | -0.4613 | -- | -- | -- | 32.05 | 87.68 | -- | -- | -- |
Manuka Inc | 671.00k | -1.14m | 3.36m | 4.00 | -- | -- | -- | 5.01 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
Gold River Productions Inc. | -100.00bn | -100.00bn | 3.38m | 1.00k | -- | 5.21 | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.11 | -- | -- | -- |
Clearmind Medicine Inc | 0.00 | -8.09m | 3.39m | -- | -- | 0.6727 | -- | -- | -30.92 | -30.92 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -109.55 | -218.20 | -180.61 | -488.96 | -- | -- | -- | -- | -- | -2.90 | 0.0184 | -- | -- | -- | -25.03 | -- | -- | -- |
Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 3.41m | 25.00 | -- | -- | -- | 0.2159 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
Atreca Inc | 0.00 | -97.76m | 3.41m | 90.00 | -- | 0.3171 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
Avenue Therapeutics Inc | 0.00 | -7.18m | 3.53m | 3.00 | -- | 0.7804 | -- | -- | -39.36 | -39.36 | 0.00 | 4.81 | 0.00 | -- | -- | 0.00 | -123.08 | -186.91 | -1,045.52 | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Tower Research Capital LLCas of 31 Mar 2024 | 1.66k | 0.07% |
Group One Trading LPas of 31 Mar 2024 | 14.00 | 0.00% |
LRI Investments LLCas of 31 Mar 2024 | 1.00 | 0.00% |
Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 0.00 | 0.00% |
UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |